Mené sur 29 patients atteints d'un cancer des glandes salivaires, cet essai prospectif de phase II évalue, selon la présence et la gravité de mucites post-traitement, la toxicité d'une radiothérapie avec modulation d'intensité combinée à une irradiation additionnelle du lit tumoral par ions carbone

IMRT and carbon ion boost for malignant salivary gland tumors : interim analysis of the COSMIC trial

Jensen, Alexandra ; Nikoghosyan, Anna ; Lossner, Karen ; Herfarth, Klaus ; Debus, Jurgen ; Munter, Marc

Purpose To evaluate toxicity in dose-escalated treatment with intensity-modulated radiotherapy (IMRT) and carbon ion boost for malignant salivary gland tumors (MSGT) of the head and neck including patients with inoperable/ incompletely resected MSGTs (R2-group) and completely resected tumors plus involved margins or perineural spread (R1-group).METHODS:COSMIC is a prospective phase II trial of IMRT (25 x 2 Gy) and carbon ion boost (8 x 3 GyE). Primary endpoint is mucositis CTCdegreesIII, [...]

Cette étude compare, du point de vue de la survie sans récidive à 5 ans, l'efficacité d'une greffe allogénique de cellules souches hématopoïétiques et de traitements alternatifs pour réduire le risque de récidive chez les patients atteints d'une leucémie myéloïde aiguë avec ou sans monosomie (2 560 patients ; 305 cas ; âge : inférieur à 61 ans)

Comparative Analysis of the Value of Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories

Cornelissen, Jan J. ; Breems, Dimitri ; van Putten, Wim L.J. ; Gratwohl, Alois A. ; Passweg, Jakob R. ; Pabst, Thomas ; Maertens, Johan ; Beverloo, H. Berna ; van Marwijk Kooy, Marinus ; Wijermans, Pierre W. ; Biemond, Bart J. ; Vellenga, Edo ; Verdonck, Leo F. ; Ossenkoppele, Gert J. ; Löwenberg, Bob

Purpose To determine to what extent allogeneic hematopoietic stem-cell transplantation (alloHSCT) quantitatively reduces relapse in acute myeloid leukemia with monosomal karyotype (MK-AML) compared with alternative postremission therapy and how it compares with other cytogenetic subcategories.Patients and Methods Of 2,560 patients (younger than age 61 years) without core-binding factor abnormalities including 305 patients with MK-AML receiving first-line induction treatment, 1,975 patients [...]

Menée sur 195 patients atteints d'un carcinome métastatique à cellules rénales et ayant subi une néphrectomie radicale entre 1989 et 2009, cette étude monocentrique caractérise les complications post-opératoires et identifie les facteurs prédictifs associés

Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC)

Silberstein, Jonathan L. ; Adamy, Ari ; Maschino, Alexandra C. ; Ehdaie, Behfar ; Garg, Tullika ; Favaretto, Ricardo L. ; Ghoneim, Tarek P. ; Motzer, Robert J. ; Russo, Paul

Study Type – Harm (case series)Level of Evidence  4What's known on the subject? and What does the study add?Radical nephrectomy for patients with metastatic renal cell carcinoma results in greater rates of morbidity than for those with less advanced disease.This study systematically characterizes complications associated with nephrectomy for metastatic RCC and identifies patient and disease characteristics that are associated with a greater risk of developing complications. Overall [...]

Cet article passe en revue les perspectives offertes par l'usage de cannabinoïdes pour le traitement des cancers

Towards the use of cannabinoids as antitumour agents

Velasco, Guillermo ; Sánchez, Cristina ; Guzmán, Manuel

Various reports have shown that cannabinoids (the active components of marijuana and their derivatives) can reduce tumour growth and progression in animal models of cancer, in addition to their well-known palliative effects on some cancer-associated symptoms. This Opinion article discusses our current understanding of cannabinoids as antitumour agents, focusing on recent insights into the molecular mechanisms of action, including emerging resistance mechanisms and opportunities for combination [...]

Menée in vitro et à l'aide de xénogreffes, cette étude met en évidence un mécanisme de rétroaction par lequel un inhibiteur de MEK induit l'activation de la voie de signalisation PI3K/AKT

MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors

Turke, Alexa B. ; Song, Youngchul ; Costa, Carlotta ; Cook, Rebecca ; Arteaga, Carlos L. ; Asara, John M ; Engelman, Jeffrey A.

The PI3K/AKT and RAF/MEK/ERK signaling pathways are activated in a wide range of human cancers. In many cases, concomitant inhibition of both pathways is necessary to block proliferation and induce cell death and tumor shrinkage. Several feedback systems have been described in which inhibition of one intracellular pathway leads to activation of a parallel signaling pathway, thereby decreasing the effectiveness of single-agent targeted therapies. In this study we describe a feedback mechanism in [...]

Cet article passe en revue les perspectives offertes par le développement d'inhibiteurs de MET, et de biomarqueurs prédictifs associés, pour le traitement des cancers

MET: a promising anticancer therapeutic target

Peters, Solange ; Adjei, Alex A.

The MET pathway is dysregulated in many human cancers and promotes tumour growth, invasion and dissemination. Abnormalities in MET signalling have been reported to correlate with poor clinical outcomes and drug resistance in patients with cancer. Thus, MET has emerged as an attractive target for cancer therapy. Several MET inhibitors have been introduced into the clinic, and are currently in all phases of clinical trials. In general, initial results from these studies indicate only a modest [...]

Menée sur un modèle murin, cette étude évalue l'activité antitumorale d'un composé appelé Lys01, un inhibiteur de l'autophagie

Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency

McAfee, Quentin ; Zhang, Zhihui ; Samanta, Arabinda ; Levi, Samuel M. ; Ma, Xiao-Hong ; Piao, Shengfu ; Lynch, John P. ; Uehara, Takeshi ; Sepulveda, Antonia R. ; Davis, Lisa E. ; Winkler, Jeffrey D. ; Amaravadi, Ravi K.

Autophagy is a lysosome-dependent degradative process that protects cancer cells from multiple stresses. In preclinical models, autophagy inhibition with chloroquine (CQ) derivatives augments the efficacy of many anticancer therapies, but CQ has limited activity as a single agent. Clinical trials are underway combining anticancer agents with hydroxychloroquine (HCQ), but concentrations of HCQ required to inhibit autophagy are not consistently achievable in the clinic. We report the synthesis [...]

Menée in vitro et in vivo, cette étude évalue l'intérêt de nouveaux composés appelés ImmTACs pour l'immunothérapie des cancers

Monoclonal TCR-redirected tumor cell killing

Liddy, Nathaniel ; Bossi, Giovanna ; Adams, Katherine J. ; Lissina, Anna ; Mahon, Tara M. ; Hassan, Namir J. ; Gavarret, Jessie ; Bianchi, Frayne C. ; Pumphrey, Nicholas J. ; Ladell, Kristin ; Gostick, Emma ; Sewell, Andrew K. ; Lissin, Nikolai M. ; Harwood, Naomi E. ; Molloy, Peter E. ; Li, Yi ; Cameron, Brian J. ; Sami, Malkit ; Baston, Emma E. ; Todorov, Penio T. ; Paston, Samantha J. ; Dennis, Rebecca E. ; Harper, Jane V. ; Dunn, Steve M. ; Ashfield, Rebecca ; Johnson, Andy ; McGrath, Yvonne ; Plesa, Gabriela ; June, Carl H. ; Kalos, Michael ; Price, David A. ; Vuidepot, Annelise ; Williams, Daniel D. ; Sutton, Deborah H. ; Jakobsen, Bent K.

T cell immunity can potentially eradicate malignant cells and lead to clinical remission in a minority of patients with cancer. In the majority of these individuals, however, there is a failure of the specific T cell receptor (TCR)–mediated immune recognition and activation process. Here we describe the engineering and characterization of new reagents termed immune-mobilizing monoclonal TCRs against cancer (ImmTACs). Four such ImmTACs, each comprising a distinct tumor-associated [...]

Menée in vitro et in vivo, cette étude évalue la faisabilité d'utiliser des salmonelles se fixant spécifiquement sur les tumeurs pour développer des traitements du cancer

A Bioluminescent Transposon Reporter-Trap Identifies Tumor-Specific Microenvironment-Induced Promoters in Salmonella for Conditional Bacterial-Based Tumor Therapy

Flentie, Kelly ; Kocher, Brandon ; Gammon, Seth T ; Novack, Deborah Veis ; McKinney, Jeffrey S ; Piwnica-Worms, David

Salmonella specifically localize to malignant tumors in vivo, a trait potentially exploitable as a delivery system for cancer therapeutics. To characterize mechanisms and genetic responses of Salmonella during interaction with living neoplastic cells, we custom designed a promoterless transposon reporter containing bacterial luciferase. Analysis of a library containing 7,400 independent Salmonella transposon insertion mutants in co-culture with melanoma or colon carcinoma cells identified five [...]

Mené sur 19 patients atteints d'une leucémie myéloïde aiguë (âge médian : 70 ans), cet essai de phase I évalue la toxicité et l'activité clinique d'un traitement combinant decitabine et bortezomib

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia

Blum, William ; Schwind, Sebastian ; Tarighat, Somayeh S. ; Geyer, Susan ; Eisfeld, Ann-Kathrin ; Whitman, Susan ; Walker, Alison ; Klisovic, Rebecca ; Byrd, John C. ; Santhanam, Ramasamy ; Wang, Hongyan ; Curfman, John P. ; Devine, Steven M. ; Jacob, Samson ; Garr, Celia ; Kefauver, Cheryl ; Perrotti, Danilo ; Chan, Kenneth K. ; Bloomfield, Clara D. ; Caligiuri, Michael A. ; Grever, Michael R. ; Garzon, Ramiro ; Marcucci, Guido

We recently reported promising clinical activity for a 10-day regimen of decitabine in older AML patients; high miR-29b expression associated with clinical response. Subsequent preclinical studies with bortezomib in AML cells have shown drug-induced miR-29b upregulation, resulting in loss of transcriptional activation for several genes relevant to myeloid leukemogenesis including DNA methyltransferases (DNMTs) and receptor tyrosine kinases (RTKs). Thus, a phase I trial of bortezomib and [...]

Mené sur 129 patients atteints d'un myélome multiple récidivant et/ou réfractaire non exposés au bortezomib, cet essai de phase II évalue, du point de vue du taux de réponse globale, le carfilzomib, un inhibiteur sélectif du protéasome

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma

Vij, Ravi ; Wang, Michael ; Kaufman, Jonathan L. ; Lonial, Sagar ; Jakubowiak, Andrzej J. ; Stewart, A. Keith ; Kukreti, Vishal ; Jagannath, Sundar ; McDonagh, Kevin T. ; Alsina, Melissa ; Bahlis, Nizar J. ; Reu, Frederic J. ; Gabrail, Nashat Y. ; Belch, Andrew ; Matous, Jeffrey V. ; Lee, Peter ; Rosen, Peter ; Sebag, Michael ; Vesole, David H. ; Kunkel, Lori A. ; Wear, Sandra M. ; Wong, Alvin F. ; Orlowski, Robert Z. ; Siegel, David S.

Carfilzomib is a selective proteasome inhibitor that binds irreversibly to its target. In phase 1 studies, carfilzomib elicited promising responses and an acceptable toxicity profile in patients with relapsed and/or refractory multiple myeloma (R/R MM). In this phase 2 multicenter, open-label study, 129 bortezomib-naïve patients with R/R MM (median of 2 prior therapies) were separated into Cohort 1, scheduled to receive intravenous (IV) carfilzomib 20 mg/m2 for all treatment cycles, and Cohort [...]

Menée in vitro et à l'aide de xénogreffes, cette étude évalue les effets d'un antagoniste du récepteur Smoothened de la voie de signalisation Hedgehog sur la réponse à une chimiothérapie à base de taxanes dans le cancer de l'ovaire

Smoothened Antagonists Reverse Taxane Resistance in Ovarian Cancer

Steg, Adam D. ; Katre, Ashwini A. ; Bevis, Kerri S. ; Ziebarth, Angela ; Dobbin, Zachary C. ; Shah, Monjri M. ; Alvarez, Ronald D. ; Landen, Charles N.

The hedgehog (HH) pathway has been implicated in the formation and maintenance of a variety of malignancies, including ovarian cancer; however, it is unknown whether HH signaling is involved in ovarian cancer chemoresistance. The goal of this study was to determine the effects of antagonizing the HH receptor, Smoothened (Smo), on chemotherapy response in ovarian cancer. Expression of HH pathway members was assessed in 3 pairs of parental and chemotherapy-resistant ovarian cancer cell lines [...]

Mené sur des cellules isolées à partir d'échantillons prélevés sur des patientes atteintes d'un cancer avancé de l'ovaire, cette étude évalue l'association entre des anomalies relatives à la voie de signalisation PI3K et la résistance thérapeutique

The association of PI3 kinase signalling and chemo-resistance in advanced ovarian cancer

Carden, Craig P ; Stewart, Adam ; Thavasu, Parames ; Kipps, Emma ; Pope, Lorna ; Crespo, Mateus ; Miranda, Susana ; Attard, Gerhardt ; Garrett, Michelle D ; Clarke, Paul A ; Workman, Paul ; de Bono, Johann S. ; Gore, Martin ; Kaye, Stan B ; Banerji, Udai

Evidence that the phosphatidylinositide-3-kinase (PI3K) pathway is deregulated in ovarian cancer is largely based on analysis of surgical specimens sampled at diagnosis and may not reflect the biology of advanced ovarian cancer. We aimed to investigate PI3K signalling in cancer cells isolated from patients with advanced ovarian cancer. Ascites samples were analysed from 88 patients, of whom 61 received further treatment. Cancer cells were immunomagnetically separated from ascites and the [...]

Mené sur 16 patients atteints d'un cancer localisé de la prostate (âge médian : 63 ans), cet essai de phase II évalue le figitumumab, un anticorps monoclonal anti IGF-IR

A Phase 2 Pharmacodynamic Study of Pre-operative Figitumumab in Patients with Localized Prostate Cancer

Chi, Kim N. ; Gleave, Martin E ; Fazli, Ladan ; Goldenberg, S Larry ; So, Alan ; Kollmannsberger, Christian ; Murray, Nevin ; Tinker, Anna V ; Pollak, Michael N.

Purpose: Activation of the insulin-like growth factor 1 receptor (IGF-IR) is implicated in prostate cancer development and progression. This study evaluated biologic and clinical effects of figitumumab, a fully human monoclonal IGF-IR antibody, in patients with localized prostate cancer. Patients and Methods: Eligible patients received figitumumab 20 mg/kg intravenously every 3 weeks for 3 cycles followed by prostatectomy. The primary endpoint was IGF-IR expression inhibition as assessed by [...]

Mené sur 38 patients atteints d'un cancer colorectal métastatique, cet essai de phase I évalue la toxicité et l'activité antitumorale du regorafenib

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Strumberg, D. ; Scheulen, M. E. ; Schultheis, B. ; Richly, H. ; Frost, A. ; Buchert, M. ; Christensen, O. ; Jeffers, M. ; Heinig, R. ; Boix, O. ; Mross, K.

Background: In a phase I dose-escalation study, regorafenib demonstrated tolerability and antitumour activity in solid tumour patients. The study was expanded to focus on patients with metastatic colorectal cancer (CRC). Methods: Patients received oral regorafenib 60–220 mg daily (160 mg daily in the extension cohort) in cycles of 21 days on, 7 days off treatment. Assessments included toxicity, response, pharmacokinetics and pharmacodynamics. Results: Thirty-eight patients with heavily [...]

Menée in vitro et à l'aide de xénogreffes, cette étude suggère l'intérêt d'une immunothérapie adoptive à l'aide de cellules NKT surexprimant l'interleukine 15 pour le traitement des neuroblastomes

IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity

Liu, Daofeng ; Song, Liping ; Wei, Jie ; Courtney, Amy N. ; Gao, Xiuhua ; Marinova, Ekaterina ; Guo, Linjie ; Heczey, Andras ; Asgharzadeh, Shahab ; Kim, Eugene ; Dotti, Gianpietro ; Metelitsa, Leonid S.

Vα24-invariant NKT cells inhibit tumor growth by targeting tumor-associated macrophages (TAMs). Tumor progression therefore requires that TAMs evade NKT cell activity through yet-unknown mechanisms. Here we report that a subset of cells in neuroblastoma (NB) cell lines and primary tumors expresses membrane-bound TNF-α (mbTNF-α). These proinflammatory tumor cells induced production of the chemokine CCL20 from TAMs via activation of the NF-κB signaling pathway, an effect that was amplified in [...]

Mené sur 304 patients atteints d'un carcinome adrénocortical de stade avancé, cet essai suédois évalue, du point de vue de la survie globale, le mitotane en combinaison avec la streptozotocine ou un protocole à base d'étoposide, de doxorubicine et de cisplatine

Combination Chemotherapy in Advanced Adrenocortical Carcinoma

Fassnacht, Martin ; Terzolo, Massimo ; Allolio, Bruno ; Baudin, Eric ; Haak, Harm ; Berruti, Alfredo ; Welin, Staffan ; Schade-Brittinger, Carmen ; Lacroix, André ; Jarzab, Barbara ; Sorbye, Halfdan ; Torpy, David J. ; Stepan, Vinzenz ; Schteingart, David E. ; Arlt, Wiebke ; Kroiss, Matthias ; Leboulleux, Sophie ; Sperone, Paola ; Sundin, Anders ; Hermsen, Ilse ; Hahner, Stefanie ; Willenberg, Holger S. ; Tabarin, Antoine ; Quinkler, Marcus ; de la Fouchardière, Christelle ; Schlumberger, Martin ; Mantero, Franco ; Weismann, Dirk ; Beuschlein, Felix ; Gelderblom, Hans ; Wilmink, Hanneke ; Sender, Monica ; Edgerly, Maureen ; Kenn, Werner ; Fojo, Tito ; Müller, Hans-Helge ; Skogseid, Britt

Background: Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. Methods: We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g [...]

Cet article analyse les travaux récents sur le traitement des mélanomes présentant la mutation BRAFV600E

The role of BRAF V600 mutation in melanoma

Ascierto, Paolo ; Kirkwood, John ; Grob, Jean-Jacques ; Simeone, Ester ; Grimaldi, Antonio ; Maio, Michele ; Palmieri, Giuseppe ; Testori, Alessandro ; Marincola, Francesco ; Mozzillo, Nicola

BRAF is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. About 50% of melanomas harbors activating BRAF mutations (over 90% V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III [...]

Mené sur 960 patients atteints d'un cancer avancé du poumon non à petites cellules, cet essai de phase III évalue, du point de vue de la survie globale, l'ajout de sunitinib à l'erlotinib

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial

Scagliotti, Giorgio V. ; Krzakowski, Maciej ; Szczesna, Aleksandra ; Strausz, Janos ; Makhson, Anatoly ; Reck, Martin ; Wierzbicki, Rafal F. ; Albert, Istvan ; Thomas, Michael ; Miziara, Jose Elias Abrao ; Papai, Zsolt S. ; Karaseva, Nina ; Thongprasert, Sumitra ; Dalmau Portulas, Elsa ; von Pawel, Joachim ; Zhang, Ke ; Selaru, Paulina ; Tye, Lesley ; Chao, Richard C. ; Govindan, Ramaswamy

Purpose Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone in non–small-cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor growth, angiogenesis, and metastasis. This phase III trial investigated overall survival (OS) for sunitinib plus erlotinib versus placebo plus erlotinib in patients with refractory NSCLC.Patients and Methods Patients previously treated with one to two chemotherapy regimens (including one [...]

Mené sur 111 patientes atteintes d'un cancer métastatique du sein résistant aux inhibiteurs d'aromatase, cet essai français de phase II évalue la toxicité et l'efficacité de l'évérolimus en combinaison avec du tamoxifène

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

Bachelot, Thomas ; Bourgier, Céline ; Cropet, Claire ; Ray-Coquard, Isabelle ; Ferrero, Jean-Marc ; Freyer, Gilles ; Abadie-Lacourtoisie, Sophie ; Eymard, Jean-Christophe ; Debled, Marc ; Spaëth, Dominique ; Legouffe, Eric ; Allouache, Djelila ; El Kouri, Claude ; Pujade-Lauraine, Eric

Purpose Cross-talk between signal transduction pathways likely contributes to hormone resistance in metastatic breast cancer (mBC). Everolimus, an oral inhibitor of the mammalian target of rapamycin, has restored sensitivity in endocrine-resistance models and shown anticancer activity in early-phase mBC clinical trials. This analysis evaluated efficacy and safety of everolimus in combination with tamoxifen in patients with mBC resistant to aromatase inhibitors (AIs).Patients and Methods This [...]

Menée sur 150 patients atteints d'un cancer localement avancé de la tête et du cou (durée médiane de suivi : 30 mois), cette étude rétrospective évalue, du point de vue du contrôle locorégional de la maladie et de la survie globale, la toxicité et l'efficacité d'une radiothérapie avec modulation d'intensité combinée à une chimiothérapie concomitante par carboplatine et paclitaxel

Intensity-Modulated Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer: Toxicities and Efficacy

Vlacich, Gregory ; Diaz, Roberto ; Thorpe, Steven W. ; Murphy, Barbara A. ; Kirby, Wyndee ; Sinard, Robert J. ; Shakhtour, Bashar ; Shyr, Yu ; Murphy, Patrick ; Netterville, James L. ; Yarbrough, Wendell G. ; Cmelak, Anthony J.

Abstract Background. Intensity-modulated radiation therapy (IMRT) and alternative chemotherapy regimens strive to maintain efficacy while minimizing toxicity in locally advanced head and neck cancer (LAHNC) treatment. Our experience with concurrent IMRT and taxane-based chemotherapy is presented.Methods. A retrospective review of 150 consecutive patients with LAHNC treated with IMRT and concurrent taxane-based chemotherapy with curative intent was performed. The IMRT fractionation regimen [...]

Cet article passe en revue les enjeux techniques, juridiques et éthiques associés à l'exploitation de bases de données rassemblant des dossiers médicaux électroniques

Mining electronic health records: towards better research applications and clinical care

Jensen, Peter B. ; Jensen, Lars J. ; Brunak, Soren

Clinical data describing the phenotypes and treatment of patients represents an underused data source that has much greater research potential than is currently realized. Mining of electronic health records (EHRs) has the potential for establishing new patient-stratification principles and for revealing unknown disease correlations. Integrating EHR data with genetic data will also give a finer understanding of genotype–phenotype relationships. However, a broad range of ethical, legal and [...]

Cet article évalue la faisabilité de mettre en application, au sein de la communauté des essais cliniques, les principes techniques et sociaux inventés par le mouvement des logiciels libres

Learning from Hackers: Open-Source Clinical Trials

Dunn, Adam G. ; Day, Richard O. ; Mandl, Kenneth D. ; Coiera, Enrico

Open sharing of clinical trial data has been proposed as a way to address the gap between the production of clinical evidence and the decision-making of physicians. A similar gap was addressed in the software industry by their open-source software movement. Here, we examine how the social and technical principles of the movement can guide the growth of an open-source clinical trial community.